Vertical Payers: “Highly Integrated” by 2026

Article

Vertical Payers: “Highly Integrated” by 2026

July 18, 2024
Authors
Topics

Welcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.

Vertical stacked puzzle pieces

HMP Market Access Insights (MAI) has been reporting on vertical payer integration since the inception of our primary payer research arm in 2022. Every year, we hear how these national players intend to further enhance their internal integration regarding business operations, policy decision making, and data sharing. However, this year we see a greater than normal ‘bump’ for what the future holds. In short, vertical payers anticipate a very high degree of integration within these critically important areas over the next few years (Figure).

Graph


Figure. Percentage of 2024 Vertical Payer Respondents Selecting “High” or “Full” Integration (N = 25).
Source: HMP Market Access Insights 2024 Payer Annual Oncology Trend Report.

  • Manufacturer contracting—greatest increase: The most anticipated area of increased integration is in contracting with manufacturers for rebates and discounts. Related data also show a 48% increase in the number of vertical payer respondents anticipating their level of integration in this area going from “None/Little/Moderate” to “High/Full.”
  • Internal data sharing—empowering payer leverage: Often related to manufacturer contracting, our respondents expect much greater integrated internal sharing of drug utilization data. Through interviews, we also know that aggregated drug-level clinical outcomes, adherence, and other data will be analyzed across entities, too.
  • Health plan vs pharmacy benefit manager (PBM): Within each vertical payer organization, respondents from the PBM entity tend to anticipate lower levels of integration in each of the 4 areas investigated than respondents from the health plan entity.

We look forward to sharing additional insights later this summer when we release our full 2024 Payer Annual Trend Report, part of our suite of Oncology Customer Insights offerings!

Be sure to check out the other reports from HMP MAI:

In the interim, please feel free to reach out to Sara Stewart with any questions you may have!

The Latest

Revolutionizing Cancer Care: EOM's Second Wind and its Current Impact on Community Oncology Practices

The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.

Ashutosh Sheth
Key takeaways from CPC+CBEx 2024
Article
Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.

Daniel Buchenberger
Figure 1: Community Oncology Actions to Address Any Potential Impact of the IRA   Source: HMP Market Access Insights 2024 Community, and Payer Oncology Trend Report.
Article
Community Oncology: Awareness v Action in the Face of the IRA

The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.

Emma Bijesse